EN DE

Shanghai Kinetic Medical Co (300326) Fair Value & Analysis

Healthcare · CN · Market cap 4.5B CNY

SK Shanghai Kinetic Medical Co 300326 · SHE
Price¥6.14
Fair Value¥3.20
Upside-47.9%
Quality66/100
Watch Shanghai Kinetic Medical Co for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Highly profitable · 20.6% net margin
Low debt · generates free cash flow
Ranks above peers (8/13)
Moderate moat 48/100
Evidence: High Range ¥2.92 – ¥4.00 Share as image

Fair value as of: Jul 9, 2026

From 26 valuation models · updated 32 days ago

Fair value updated Jul 9, 2026, revised from ¥3.62 to ¥3.20 (−11.6%) since Jun 24, 2026. Share price −0.3% over the past month.

A solid business, but screening 48% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (¥4.00). The favourable scenario is already priced in.
  • Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

¥13.94 ¥3.64 Fair Value ¥3.20 Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.

How to read this chart

60‑month range ¥3.64 – ¥13.94 · fair‑value band ¥2.92 – ¥4.00 · the ¥6.14 price screens above the ¥3.20 fair value. Dashed = 300-day average. As of Jul 9, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Shanghai Kinetic Medical Co (300326) currently trades at ¥6.14, while our model-based Fair Value estimate is ¥3.20, implying the stock looks roughly 47.9% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Shanghai Kinetic Medical Co generated revenue of 869M CNY at a net margin of 20.6%. Revenue declined 35.4% year over year. It earns a return on equity of 5.9%. The balance sheet holds a net cash position of 80.0M CNY. Fundamentals as of Jul 9, 2026

Our scenario range runs from ¥2.92 (bear case) to ¥4.00 (bull case); at ¥6.14, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 16% below its 52-week high and 38% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -48%, 300326 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF ¥2.60 ¥4.63 ¥7.64 80
Residual Income ¥2.97 ¥2.94 ¥2.68 76
Rev-Margin DCF ¥2.09 ¥3.37 ¥5.13 74
All 26 models by family
DCF Models
FCF DCF ¥2.65 ¥4.59 ¥8.61 38
Owner Earnings ¥2.90 ¥5.26 ¥9.52 31
5Y Revenue Exit ¥2.09 ¥3.41 ¥5.24 39
5Y EBITDA Exit ¥2.80 ¥4.96 ¥7.79 41
5Y P/E Exit ¥3.10 ¥5.62 ¥8.65 38
10Y Revenue Exit ¥2.21 ¥3.55 ¥5.72 36
10Y EBITDA Exit ¥2.73 ¥4.70 ¥7.92 37
10Y P/E Exit ¥2.93 ¥5.19 ¥8.67 35
Earnings-Based
Graham-Dodd ¥1.28 ¥7.13 ¥9.90 54
Lynch FV ¥1.99 ¥2.85 ¥3.70 50
PEG = 1.0 ¥1.99 ¥2.85 ¥3.70 46
EPV ¥1.67 ¥1.87 ¥2.04 59
Dividend Discount
Gordon GGM ¥0.0600 ¥0.1100 ¥0.1700 70
DDM Multi-Stage ¥0.0600 ¥0.1000 ¥0.1200 61
Multiples
P/E Multiple ¥3.10 ¥4.14 ¥5.17 63
P/S Multiple ¥2.40 ¥3.20 ¥4.00 58
P/B Multiple ¥2.40 ¥3.20 ¥4.00 55
EV/EBIT ¥2.38 ¥3.05 ¥3.71 53
EV/EBITDA ¥3.02 ¥3.90 ¥4.78 54
EV/Revenue ¥1.81 ¥2.42 ¥3.03 43
Asset-Based
NCAV (Graham) ¥2.00 ¥2.68 ¥3.99 50
Growth DCF
Growth DCF ¥2.60 ¥4.63 ¥7.64 80
Rev-Margin DCF ¥2.09 ¥3.37 ¥5.13 74
Economic Profit
Residual Income ¥2.97 ¥2.94 ¥2.68 76
ROIC Compounder ¥1.67 ¥1.87 ¥2.04 72
Growth Earnings
Growth-Adj P/E ¥3.06 ¥4.38 ¥5.69 68

Widest divergence: DCF Models (¥4.70) versus Dividend Discount (¥0.1000). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) 869M CNY
Revenue growth (YoY) -35.4%
Net margin 20.6%
Return on equity 5.9%
Free cash flow 123M CNY FY2025
P/E ratio 25.2
More key figures
Operating margin 13.8%
EPS (TTM) ¥0.2500
EPS growth (YoY) +204%
Net cash 80.0M CNY FY2024

Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 66/100

Of which business quality 64 · Market factors (momentum, volatility) 59

Profitability 35
Margins and returns on capital today
Quality Growth 54
Are margins and returns improving?
Cashflow 60
Earnings quality: real cash, not paper profit
Fin. Strength 81
Balance sheet, leverage, solvency risk
Investment 89
Disciplined investing over empire-building
Low Volatility 80
Calm price path (market factor)
Momentum 46
Price trend over the last 3–12 months (market factor)
52W Momentum 57
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Shanghai Kinetic Medical Co., Ltd, together with its subsidiaries, engages in the research, development, manufacturing, and sale of medical devices in China and internationally.

Full company description

Shanghai Kinetic Medical Co., Ltd, together with its subsidiaries, engages in the research, development, manufacturing, and sale of medical devices in China and internationally. The company offers invasive spinal, invasive vertebroplasty, radiofrequency ablation, orthopedic trauma implant equipment, artificial organs, orthopedic surgical instruments, and other medical products, as well as surgical energy platforms and consumables. It is also involved in the provision of cleaning and sterilization solutions for medical devices, equipment, and medical and sanitary materials and supplies; technical consultation; after-sales technical services; and production and sale of teaching aids. The company exports its products. Shanghai Kinetic Medical Co., Ltd was founded in 2005 and is headquartered in Shanghai, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Shanghai Kinetic Medical Co reported revenue of ¥963M in FY2025 versus ¥1.3B in FY2021, a compound −6.7%/yr. Reported net income was ¥135M in FY2025, compounding −4.4%/yr from FY2021.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
963M CNY
Latest YoY
−2.2%
Avg. growth/yr (3Y)
−6.2%
Avg. growth/yr (5Y)
−1.9%
Avg. growth/yr (17Y)
+24.5%
Revenue −6.7%/yr
FY21 ¥1.3B
FY22 ¥1.2B
FY23 ¥956M
FY24 ¥985M
FY25 ¥963M
Net income −4.4%/yr
FY21 ¥162M
FY22 −¥21.3M
FY23 ¥113M
FY24 −¥106M
FY25 ¥135M

300326 screens 48% overvalued. Compare with Abbott Laboratories, →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Shanghai Kinetic Medical Co Fair Value". https://www.fairvalue-calculator.com/stock/300326

Peer Group

Medical Devices · 351 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 66 · Top 25%
Fair Value upside −48% · Below median
Return on equity (TTM) 6% · Above median
Return on assets 1% · Below median
Net margin (TTM) 21% · Top 25%
Operating margin (TTM) 14% · Above median
Revenue growth -35% · Bottom 25%
Debt / equity 0.00× · Lower than median

Valuation Multiples vs Medical Devices median · lower = cheaper

P/E (TTM) 25.2× · Cheaper than median
P/B 1.58× · Cheaper than median
P/S (TTM) 5.20× · Pricier than 75% of peers
P/FCF 5.5× · Cheaper than median
EV/EBITDA 44.0× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 0 · sector 27
PAST 23 · sector 8
HEALTH 100 · sector 97
DIVIDEND 0 · sector 38

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $100.68 $74.79 -26%
Stryker Corporation SYK $316.44 $186.28 -41%
Medtronic plc MDT $83.56 $65.57 -22%
Boston Scientific Corporation BSX $43.04 $38.44 -11%
Edwards Lifesciences Corporation EW $85.73 $41.02 -52%
Siemens Healthineers AG SHL €34.59 €33.87 -2%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥149.43 ¥147.63 -1%
Shanghai United Imaging Healthcare Co 688271 ¥109.00 ¥43.60 -60%
Demant A/S DEMANT kr 276.60 kr 161.17 -42%
Getinge AB GETIB kr 206.80 kr 192.14 -7%

Compare Shanghai Kinetic Medical Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Shanghai Kinetic Medical Co (300326) overvalued or undervalued?
As of Jul 9, 2026, our model estimates a fair value of ¥3.20 versus a price of ¥6.14, about −48% (overvalued).
What is the fair value of 300326?
Our model-based fair value for Shanghai Kinetic Medical Co is ¥3.20 (as of Jul 9, 2026), built from audited fundamentals. The current price is ¥6.14.
What is the quality score of 300326?
Shanghai Kinetic Medical Co has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Shanghai Kinetic Medical Co (300326)?
Shanghai Kinetic Medical Co reported trailing-twelve-month revenue of about 869M CNY (latest available figure, as of Jul 9, 2026).
What is the net profit margin of 300326?
The net profit margin of Shanghai Kinetic Medical Co is about 20.6%, meaning it keeps roughly 20.6% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Shanghai Kinetic Medical Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.